Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction
Clinical trial NCT02266355 · COMPLETED
Trial details
- NCT number
- NCT02266355
- Sponsor
- Yale University
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-01
- Primary completion
- 2018-02-27
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.